AIMS: Inflammatory cytokines, particularly tumour necrosis factor-α (TNFα), are thought to promote arterial disease through a variety of mechanisms leading to arteriosclerosis and atherosclerosis. We reviewed the existing evidence of the effect of anti-TNFα treatment on arteriosclerosis and atherosclerosis in chronic inflammatory disease. METHODS: We performed a systematic review of studies examining effects of monoclonal antibodies against TNFα on subclinical measures of arteriosclerosis (arterial pulse wave velocity) and atherosclerosis (endothelial function measured by flow-mediated dilation or forearm blood flow responses to endothelium-dependent agonists, and common carotid intima-media thickness). RESULTS: We identified 60 studies (of 854 potential studies identified using a systematic search) in which effects of anti-TNFα biologics on these measures were assessed in patients receiving anti-TNFα therapy for a clinical indication (usually an inflammatory disease such as an inflammatory arthritis, psoriasis or inflammatory bowel disease). Of these, only 6 were randomised clinical controlled trials. Whilst many observational studies and noncontrolled studies reported positive findings, positive finding were reported in only 1 of 6 randomised clinical controlled trials. CONCLUSIONS: There is no strong evidence for an effect of anti-TNFα biologics on the subclinical measures of arteriosclerosis or atherosclerosis examined in this review. This does not exclude a positive effect of TNFα biologics on clinical outcomes through alternate pathways including those induced by remission of the primary inflammatory disease.
AIMS: Inflammatory cytokines, particularly tumour necrosis factor-α (TNFα), are thought to promote arterial disease through a variety of mechanisms leading to arteriosclerosis and atherosclerosis. We reviewed the existing evidence of the effect of anti-TNFα treatment on arteriosclerosis and atherosclerosis in chronic inflammatory disease. METHODS: We performed a systematic review of studies examining effects of monoclonal antibodies against TNFα on subclinical measures of arteriosclerosis (arterial pulse wave velocity) and atherosclerosis (endothelial function measured by flow-mediated dilation or forearm blood flow responses to endothelium-dependent agonists, and common carotid intima-media thickness). RESULTS: We identified 60 studies (of 854 potential studies identified using a systematic search) in which effects of anti-TNFα biologics on these measures were assessed in patients receiving anti-TNFα therapy for a clinical indication (usually an inflammatory disease such as an inflammatory arthritis, psoriasis or inflammatory bowel disease). Of these, only 6 were randomised clinical controlled trials. Whilst many observational studies and noncontrolled studies reported positive findings, positive finding were reported in only 1 of 6 randomised clinical controlled trials. CONCLUSIONS: There is no strong evidence for an effect of anti-TNFα biologics on the subclinical measures of arteriosclerosis or atherosclerosis examined in this review. This does not exclude a positive effect of TNFα biologics on clinical outcomes through alternate pathways including those induced by remission of the primary inflammatory disease.
Authors: M Turiel; L Tomasoni; S Sitia; S Cicala; L Gianturco; C Ricci; F Atzeni; V De Gennaro Colonna; M Longhi; P Sarzi-Puttini Journal: Cardiovasc Ther Date: 2010-10 Impact factor: 3.023
Authors: Alper M van Sijl; Izhar C van Eijk; Mike J L Peters; Erik H Serné; Irene E van der Horst-Bruinsma; Yvo M Smulders; Michael T Nurmohamed Journal: Ann Rheum Dis Date: 2013-10-03 Impact factor: 19.103
Authors: P I Sidiropoulos; P Siakka; K Pagonidis; A Raptopoulou; H Kritikos; D Tsetis; D T Boumpas Journal: Scand J Rheumatol Date: 2009 Jan-Feb Impact factor: 3.641
Authors: A Ferrante; A R Giardina; F Ciccia; G Parrinello; G Licata; G Avellone; E Giardina; R Impastato; Giovanni Triolo Journal: Rheumatol Int Date: 2009-12 Impact factor: 2.631
Authors: Hester M Den Ruijter; Sanne A E Peters; Todd J Anderson; Annie R Britton; Jacqueline M Dekker; Marinus J Eijkemans; Gunnar Engström; Gregory W Evans; Jacqueline de Graaf; Diederick E Grobbee; Bo Hedblad; Albert Hofman; Suzanne Holewijn; Ai Ikeda; Maryam Kavousi; Kazuo Kitagawa; Akihiko Kitamura; Hendrik Koffijberg; Eva M Lonn; Matthias W Lorenz; Ellisiv B Mathiesen; Giel Nijpels; Shuhei Okazaki; Daniel H O'Leary; Joseph F Polak; Jackie F Price; Christine Robertson; Christopher M Rembold; Maria Rosvall; Tatjana Rundek; Jukka T Salonen; Matthias Sitzer; Coen D A Stehouwer; Jacqueline C Witteman; Karel G Moons; Michiel L Bots Journal: JAMA Date: 2012-08-22 Impact factor: 56.272
Authors: Carlos Gonzalez-Juanatey; Ana Testa; Alberto Garcia-Castelo; Carlos Garcia-Porrua; Javier Llorca; Miguel A Gonzalez-Gay Journal: Arthritis Rheum Date: 2004-06-15
Authors: F Del Porto; B Laganà; S Lai; I Nofroni; F Tinti; M Vitale; E Podestà; A P Mitterhofer; R D'Amelio Journal: Rheumatology (Oxford) Date: 2007-04-20 Impact factor: 7.580
Authors: A D Booth; D R W Jayne; R K Kharbanda; C M McEniery; I S Mackenzie; J Brown; I B Wilkinson Journal: Circulation Date: 2004-03-22 Impact factor: 29.690
Authors: Annelies B Blanken; Reinder Raadsen; Rabia Agca; Alper M van Sijl; Yvo M Smulders; Michael T Nurmohamed Journal: Rheumatol Int Date: 2022-10-21 Impact factor: 3.580